gabapentin and pregabalin on neuropathy caused by Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Comparative study of the effect of gabapentin and pregabalin on neuropathy caused by Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200217046523N16

Enrollment

Registered

2021-06-13

Start date

2021-08-08

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic inflammatory demyelinating polyneuropathy. Inflammatory polyneuropathy

Interventions

Intervention 1: Intervention group 1: Patients in the first group will be treated with 37.5 mg of venlafaxine daily with 100 to 500 mg of gabapentin daily. This treatment will continue for patients fo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: CIDP-induced neuropathy based on neurologist diagnosis Age over 18 years No other underlying disease that causes neuropathy Satisfaction with participation in this study

Exclusion criteria

Exclusion criteria: Hypersensitivity to venlafaxine, gabapentin and pregabalin Dissatisfaction with continuing the study

Design outcomes

Primary

Measure	Time frame
Intensity of patients' body pain. Timepoint: Before the intervention and once every three months for a year. Method of measurement: Visual Analogue Scale.;Severity of neuropathic pain. Timepoint: Before the intervention and once every three months for a year. Method of measurement: Short form of McGill Pain Questionnaire (SF-MPQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKeyvan Basiri

Esfahan University of Medical Sciences

basirikeivan@gmail.com+98 31 3668 0042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026